Novavax (NVAX) to Release Quarterly Earnings on Tuesday

Novavax (NASDAQ:NVAX) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Novavax to post earnings of ($0.87) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The business had revenue of $415.50 million for the quarter, compared to the consensus estimate of $458.57 million. During the same quarter in the prior year, the firm earned $0.58 earnings per share. Novavax’s revenue was down 2.1% compared to the same quarter last year. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Price Performance

Shares of NVAX opened at $8.91 on Friday. The firm has a 50-day simple moving average of $11.68 and a two-hundred day simple moving average of $12.32. The stock has a market cap of $1.43 billion, a PE ratio of -3.23 and a beta of 2.10. Novavax has a 1-year low of $3.53 and a 1-year high of $23.86.

Analysts Set New Price Targets

A number of brokerages have issued reports on NVAX. JPMorgan Chase & Co. boosted their target price on Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Monday, August 12th. B. Riley reiterated a “buy” rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, Jefferies Financial Group lowered their target price on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Novavax has an average rating of “Hold” and an average target price of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.